AI Articles and Analysis about Data management

AstraZeneca is a global biopharmaceutical company that researches, develops, manufactures, and markets prescription drugs and vaccines. Its key therapeutic areas include oncology, cardiovascular, renal, metabolism, respiratory, and immunology. In 2022, the company reported revenue of $42.67 billion and a profit of $4.08 billion. The company has a significant global presence, employing around 89,900 people across more than 60 countries as of 2023.

As stakeholders in the life sciences and healthcare industries rush to adopt GenAI and integrate it into their projects and processes, they are walking a tightrope. GenAI will play a vital role in the future of healthcare in ways that we can hardly yet imagine; on the other hand, concerns like patient data privacy and potential inaccuracies have led many to take a cautious approach. 

This interview analysis is sponsored by Pieces and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

This interview analysis is sponsored by Arkestro and was written, edited, and published in alignment with our Emerj sponsored content guidelines. Learn more about our thought leadership and content creation services on our Emerj Media Services page.

Capital One, founded in 1994 and headquartered in McLean, Virginia, has become a prominent player in the financial services sector, mainly known for its credit card offerings, auto loans, banking, and savings accounts. With operations primarily spanning the United States, the company boasts a workforce of approximately 52,000 employees. As a technology-focused financial institution, Capital One is dedicated to leveraging cutting-edge innovations to enhance customer experience and streamline operations.

The asset management industry is going through several challenges, like the prolonged low-interest rate environment, dwindling margins, increased cost pressures, and squeezed profitability. Meanwhile, exponential growth in data volumes has overwhelmed legacy data management systems and analytical tools, making it tiring to process and extract valuable insights from the deluge of information. 

According to research from the American Society for Biochemistry and Molecular Biology, nine out of 10 drugs fail to make it to market in the clinical trials process. Researchers in the cited studies found that 40-50% of these failures are due to a lack of clinical efficacy, meaning that the drug is not able to produce its intended effect in people, and 30% were due to unmanageable toxicity or side effects.

Business processes are defined in large part by the data within an organization. Value-driven data, by definition, represents higher-quality data. The importance of high-quality data cannot be overlooked. Research from MIT, even from before the pandemic AI boom, showed that insufficient data can cost as much as 25% of the revenue for most companies.